CSIMarket



HOSPIRA, INC.  (HSP)
Other Ticker:  
 
 

HSP's Revenue Growth by Quarter and Year

Hospira,'s Revenue results by quarter and year




HSP Revenue (in millions $) FY 2014 FY 2013 FY 2012 FY 2011
IV Quarter December - 1,084.40 1,098.90 1,014.00
III Quarter September 1,150.60 1,008.20 994.00 976.70
II Quarter June 1,135.80 1,026.20 1,033.30 1,064.10
I Quarter March 1,050.80 884.00 965.90 1,002.30
FY   3,337.20 4,002.80 4,092.10 4,057.10



HSP Revenue third quarter 2014 Y/Y Growth Comment
HOSPIRA, INC. achieved in the third quarter 2014, above Company average Revenue increase of 14.12% year on year, to $ 1,150.60 millions.

Looking into third quarter 2014 results within Major Pharmaceutical Preparations industry 61 other companies have achieved higher Revenue growth. While Hospira, Inc.' s Revenue growth of 14.12% ranks overall at the positon no. 1123 in the third quarter 2014.




HSP Revenue ( Y/Y Growth %) 2014
2013 2012 2011
IV Quarter December - -1.32 % 8.37 % 2.21 %
III Quarter September 14.12 % 1.43 % 1.77 % 2.89 %
II Quarter June 10.68 % -0.69 % -2.89 % 9.9 %
I Quarter March 18.87 % -8.48 % -3.63 % -0.53 %
FY   - -2.18 % 0.86 % 3.57 %

Financial Statements
Hospira,'s third quarter 2014 Revenue $ 1,150.60 millions HSP's Income Statement
Hospira,'s third quarter 2013 Revenue $ 1,008.20 millions Quarterly HSP's Income Statement
New: More HSP's historic Revenue Growth >>


HSP Revenue (Quarter on Quarter Growth %)

2014
2013 2012 2011
IV Quarter December - 7.56 % 10.55 % 3.82 %
III Quarter September 1.3 % -1.75 % -3.8 % -8.21 %
II Quarter June 8.09 % 16.09 % 6.98 % 6.17 %
I Quarter March -3.1 % -19.56 % -4.74 % 1.03 %
FY (Year on Year)   - -2.18 % 0.86 % 3.57 %




Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #163
Overall #1123

Revenue Y/Y Growth Statistics
High Average Low
33.91 % 5.76 % -8.48 %
(Dec. 30. 2007)   (March 31, 2013)
Revenue third quarter 2014 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #163
Overall #1123
Revenue Y/Y Growth Statistics
High Average Low
33.91 % 5.76 % -8.48 %
(Dec. 30. 2007)   (March 31, 2013)

Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014

Hospira,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
16.09 % 1.43 % -19.56 %
(June 30, 2013)  


HSP's III. Quarter Q/Q Revenue Comment
HOSPIRA, INC. achieved in the III. Quarter 2014 below company average Revenue growth of 1.3% quarter on quarter, to $ 1,150.60 millions.

Albeit the III. Quarter 2014 Hospira,'s Revenue quarter on quarter growth was beneath the ordinary of 1.43 %, that was still good news, as the current surge, eclipses the -1.75% Revenue rise in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue quarter on quarter growth. While Hospira,'s Revenue growth quarter on quarter, overall rank is 2162.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #229
Overall #2162
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #70
Healthcare Sector #229
Overall #2162
Revenue Q/Q Growth Statistics
High Average Low
16.09 % 1.43 % -19.56 %
(June 30, 2013)  


HSP's III. Quarter Q/Q Revenue Comment
HOSPIRA, INC. achieved in the III. Quarter 2014 below company average Revenue growth of 1.3% quarter on quarter, to $ 1,150.60 millions.

III. Quarter 2014 Revenue sequential growth appear to be a mixed bag, even if beneath the ordinary increase of 1.43 %, yet it demonstrates a quite improvement compare to the -1.75% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 69 other companies have achieved higher Revenue quarter on quarter growth. While Hospira,'s Revenue growth quarter on quarter, overall rank is 2162.


Hospira,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep. 30, 2014)
12 Months Ending
(June 30. 2014)
12 Months Ending
(March 31, 2014)
12 Months Ending
(Dec 31 2013)
12 Months Ending
(Sep. 30, 2013)
Cumulative Revenue 12 Months Ending $ 4,421.60 $ 4,279.20 $ 4,169.60 $ 6,921.20 $ 4,017.30
Y / Y Revenue Growth (TTM) 10.06 % 6.9 % 3.97 % 69.14 % 0.25 %
Year on Year Revenue Growth Overall Ranking # 1301 # 1476 # 1472 # 1472 # 1472
Seqeuential Revenue Change (TTM) 3.33 % 2.63 % 4.17 % 72.28 % 0.35 %
Seq. Revenue Growth (TTM) Overall Ranking # 1192 # 1362 # 0 # 0 # 1219




Cumulative Revenue growth Comment
Hospira, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10.06% year on year, to $ 4,422 millions if the fiscal year would have ended in Sep. 30, 2014.
Hospira,'s trailing twelve months Revenue growth was higher than company's average 7.3% and higher than 6.9% growth in June 30. 2014.
But from twelve months ended June 30. 2014 growth rate was less at 3.33 % from $4279.2 millions achieved in twelve months ending a quarter before Brayden Schneider went on.
It appears to be slowdown in progress, more obvious observing the average Q/Q TTM historic advancement what is higher at 3.35%.
The momentum was even higher sequentially showed at 3.33 % increase from $4279.2 millions in twelve months ending a quarter before.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1301, from total ranking in previous quarter at 1476.

Revenue TTM Q/Q Growth Statistics
High Average Low
72.28 %
3.35 %
-2.02 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 57
Healthcare Sector # 156
Overall # 1301

Revenue TTM Y/Y Growth Statistics
High Average Low
69.14 %
7.3 %
-2.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 168
S&P 500 # 1192
Cumulative Revenue growth Comment
Hospira, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10.06% year on year, to $ 4,422 millions if the fiscal year would have ended in Sep. 30, 2014.
Hospira,'s trailing twelve months Revenue growth was higher than company's average 7.3% and higher than 6.9% growth in June 30. 2014.
But sequential growth rate was less at 3.33 % from $4279.2 millions achieved in twelve months ending a quarter June 30. 2014.
We witness drop-off in progress, more evident if you pay attention to the typical sequential Revenue rise what is better at3.35%.
The growth was much stronger from twelve months ended June 30. 2014 clinched at 3.33 % jump from $4279.2 millions in twelve months ending a quarter June 30. 2014.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1301, from total ranking in previous quarter at 1476.

Revenue TTM Q/Q Growth Statistics
High Average Low
72.28 %
3.35 %
-2.02 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 57
Healthcare Sector # 156
Overall # 1301

Revenue TTM Y/Y Growth Statistics
High Average Low
69.14 %
7.3 %
-2.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 168
S&P 500 # 1192




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HSP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for HSP's Competitors
Revenue Growth for Hospira,'s Suppliers
Revenue Growth for HSP's Customers

You may also want to know
HSP's Annual Growth Rates HSP's Profitability Ratios HSP's Asset Turnover Ratio HSP's Dividend Growth
HSP's Roe HSP's Valuation Ratios HSP's Financial Strength Ratios HSP's Dividend Payout Ratio
HSP's Roa HSP's Inventory Turnover Ratio HSP's Growth Rates HSP's Dividend Comparisons



Companies with similar Revenue growth for the quarter ending Sep. 30, 2014 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep. 30, 2014
Anika Therapeutics Inc 24.22%$ 24.225 millions
Orbital Energy Group Inc.24.18%$ 24.183 millions
Heska Corporation23.93%$ 23.927 millions
Tearlab Corp23.89%$ 23.889 millions
Vivus Inc23.73%$ 23.734 millions
Wright Medical Group N v 23.71%$ 23.709 millions
Zogenix Inc 22.73%$ 22.726 millions
Insulet Corporation22.72%$ 22.719 millions
Edwards Lifesciences Corporation22.56%$ 22.559 millions
Alnylam Pharmaceuticals Inc 22.03%$ 22.033 millions
Quidel Corporation21.82%$ 21.819 millions
Regeneron Pharmaceuticals Inc 21.57%$ 21.567 millions
Addus Homecare Corporation21.32%$ 21.324 millions
Antares Pharma Inc 19.30%$ 19.295 millions
Rti Surgical Holdings Inc 19.04%$ 19.037 millions
Cyanotech Corp18.98%$ 18.975 millions
Retractable Technologies inc 18.85%$ 18.847 millions
Panbela Therapeutics Inc 18.43%$ 18.427 millions
Celgene Corp18.38%$ 18.383 millions
U S Physical Therapy Inc18.06%$ 18.057 millions
Amag Pharmaceuticals inc 17.94%$ 17.940 millions
Mylan N v 17.91%$ 17.912 millions
Abaxis Inc17.65%$ 17.648 millions
International Stem Cell Corporation17.54%$ 17.545 millions
Nephros Inc 17.46%$ 17.464 millions
Apyx Medical Corporation17.16%$ 17.156 millions
Abiomed Inc.17.12%$ 17.123 millions
Iqvia Holdings Inc 17.08%$ 17.075 millions
Option Care Health Inc 16.79%$ 16.794 millions
Allergan plc16.58%$ 16.578 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SUMR's Profile

Stock Price

SUMR's Financials

Business Description

Fundamentals

Charts & Quotes

SUMR's News

Suppliers

SUMR's Competitors

Customers & Markets

Economic Indicators

SUMR's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071